As per the research report, the size of the Asia Pacific Thin Film Drugs market is valued at USD 3.04 billion in 2019 and is expected to reach USD 4.97 billion by 2024 at 10.32% CAGR during the forecast period 2019 to 2024.
Thin film drugs are made of hydrophilic polymers that readily dissolve on the buccal cavity. These drugs are administered orally and enter the systemic circulation of the body upon absorption on the tongue.
The growing demand for efficient drug delivery systems has amplified the uptake of thin film drugs due to their efficiency and effectiveness. The convenience of transportation and storage has encouraged patients to opt for these drugs. Thin film drugs also permit precise dosages to accomplish desired outcomes and thereby aid the market growth. The growing investments in research and development of newer polymeric thin films as a method of drug deliver has also invigorated the market growth. Thin film drugs are poised to gain attention in the healthcare industry as eliminate the drawbacks associated with conventional forms of dosages such as inconvenience of administration, lower bioavailability, and patient non-compliance among others.
This research report segmented and sub-segmented into the following categories:
Asia Pacific is expected to witness the highest growth rate in the coming years.
The Top companies leading in the APAC Thin Film Drugs Market profiled in the report are Pfizer Inc., Novartis AG, Wolters Kluwer, Solvay, Allergan plc., Sumitomo Dainippon Pharma Co. Ltd., Indivior Plc., MonoSol Rx, IntelGenx Corp., ZIM Laboratories Limited, and IntelGenx Corp.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Oral Thin Film
5.1.2.1 Sublingual Film
5.1.2.2 Fully Dissolving Dental/Buccal Film
5.1.3 Transdermal Thin Film
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Disease Indication
5.2.1 Introduction
5.2.2 Schizophrenia
5.2.3 Migraine
5.2.4 Opioid Dependence
5.2.5 Nausea and Vomiting
5.2.6 Y-o-Y Growth Analysis, By Disease Indication
5.2.7 Market Attractiveness Analysis, By Disease Indication
5.2.8 Market Share Analysis, By Disease Indication
5.3 Distribution Channel
5.3.1 Introduction
5.3.2 Hospital Pharmacies
5.3.3 Drug Store
5.3.4 Retail Pharmacies
5.3.5 E-Commerce
5.3.6 Others
5.3.7 Y-o-Y Growth Analysis, By Distribution Channel
5.3.8 Market Attractiveness Analysis, By Distribution Channel
5.3.9 Market Share Analysis, By Distribution Channel
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Disease Indication
6.1.3.4 By Distribution Channel
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Disease Indication
6.1.4.4 By Distribution Channel
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Disease Indication
6.1.5.4 By Distribution Channel
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Pfizer Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis AG
8.3 Wolters Kluwer
8.4 Solvay
8.5 Allergan plc.
8.6 Sumitomo Dainippon Pharma Co. Ltd.
8.7 Indivior Plc.
8.8 MonoSol Rx
8.9 IntelGenx Corp.
8.10 ZIM Laboratories Limited
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
